medigraphic.com
Colegio de Medicina Interna de México.

2016, Number 3

<< Back Next >>

Med Int Mex 2016; 32 (3)

Antibiotic most related to colitis due to antimicrobial in hospitalized patients

Sierra-Hernández A, Estrada- Hernández LO

Language: Spanish
References: 30
Page: 330-340
PDF size: 758.48 Kb.


ABSTRACT

In the hospital setting antibiotic-associated colitis has become an important nosocomial infection worldwide. The interruption of the microbiome is important to enable the growth of spores of Clostridium difficile in the colon and develop an infection; studies show that it takes at least 12 months before to start to regularise the microbiome after seven days of continuous administration of clindamycin; therefore it is recommended the administration of antibiotics in a discriminatory way. In Mexico we lack enough information to enable us to know the casuistry of such infections in order to perform the appropriate prevention. This article includes statistical data on patients who have developed Clostridium difficile infection by antimicrobials, in a nosocomial manner, at Hospital Regional Lic. Adolfo López Mateos, Mexico City.


REFERENCES

  1. Rohlke F, Stollman N. Fecal microbiota transplantation in relapsing Clostridium difficile infection. Ther Adv Gastroenterol 2012;5:403-420.

  2. Rodríguez E, Gamboa M, Camacho Z. Etiología anaerobia de la diarrea nosocomial asociada a antibióticos en adultos mayores. Revista Biomédica 2010;21:13-20.

  3. Balassiano IT, et al. Clostridium difficile: a problem of concern in developed countries and still a mystery in Latin America. J Med Microbiol 2012;61:169-179.

  4. Dumyati G, et al. Community-associated Clostridium difficile Infections, Monroe County, New York, USA. Emerging Infectious Diseases 2012;18:392-400.

  5. Poutanen SM, Simor AE. Clostridium difficile-associated diarrhea in adults. CMAJ 2004;171:51-58.

  6. Chachaty E, et al. Presence of Clostridium difficile and antibiotic and B-lactamase activities in feces of volunteers treated with oral cefixime, oral cefpodoxime proxetil, or placebo. Antimicorb. Agents Chemother 1992;36:2009- 2013.

  7. Zacharioudakis IM, Zervou FN, Pliakos EE, Ziakas PD, Mylonakis E. Colonization with toxinogenic C. difficile upon hospital admission, and risk of infection: a systematic review and meta-analysis. Am J Gastroenterol 2015;110:381.

  8. Camacho-Ortiz A, et al. First report of Clostridium difficile NAP1/027 in a Mexican hospital. PLoS One 2015;10:1-10.

  9. Camacho-Ortiz A y col. Comportamiento clínico de la enfermedad asociada a Clostridium difficile: estudio de casos y controles, XXXIII Congreso Anual de la Asociación Mexicana de Infectología y Microbiología. Clínica A. C. 2008. León, Guanajuato, México, mayo de Resumen B8.

  10. Monge D, et al. Factores de riesgo de infección por Clostridium difficile en pacientes hospitalizados. Med Clin (Barc) 2011;137:575-580.

  11. Owens RC, et al. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008;46:19-31.

  12. O’Connor JR, et al. Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology 2009;136:1913-1924.

  13. Ruiz Pascual MV, et al. Diarrea por Clostridium difficile en relación con levofloxacino. SEMERGEN 2004;30:356-359.

  14. Gerding DN, et al. The epidemiology of Clostridium difficile infection inside and outside health care institutions. Infect Dis Clin N Am 2015;29:37-50.

  15. Infect Control Hosp Epidemiol 2010;31:431-455.

  16. Surawtcz CM. Am J Gastroenterol 2013;08:478-98.

  17. United Kingdom: National Health Service; 2012.

  18. Am J Gastroenterol 2013; 108:478-498; doi:10.1038/ ajg.2013.4; published online 26 February 2013.

  19. Planche T, Wilcox M. Diagnostic pitfalls in Clostridium difficile infection. Infect Dis Clin N Am 29:63-82.

  20. Bergogne-Bérézin. Treatment and prevention of antibiotic associated diarrhea. Int J Antimicrob Agents 2000;16:521- 526.

  21. Fadi Yassin S, et al. Pseudomembranous colitis surgery treatment & management. Medscape 2013.

  22. Haraguchi M, et al. Colostomy with vancomycin administration as an effective treatment for toxic megacolon associated with fulminant pseudomembranous colitis: A case report. Asian J Surg 2004;27:236-237.

  23. Stein HD, et al. Pseudomembranous colitis as a cause of early colostomy dysfunction. J Clin Gastroenterol 1994;18:165-6.

  24. Prassler R. Percutaneous endoscopic colostomy in antibiotic-induced pseudomembranous colitis. Dtsch Med Wochenschr 2008;133:2268-2271.

  25. Guidelines for Diagnosis, Treatment, and Prevention of Clostridium difficile infections. Am J Gastroenterol 2013.

  26. Surawicz CM, et al. Guidelines for diagnosis, treatment and prevention of Clostridium difficile infections. Am J Gastroenterol 2013; 108:478-498; doi:10.1038/ajg.2013.4; published online 26 February 2013.

  27. Remes-Troche JM. Diarrea asociada con infección por Clostridium difficile, ¿es tiempo de preocuparnos en México? Rev Gastroenterol Mex 2012;77:58-59.

  28. Planche T, et al. Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C. difficile infection. Lancet Infect Dis 2013;13:936-945.

  29. Oldfield IV EC, et al. Clinical update for the diagnosis and treatment of Clostridium difficile infection. World J Gastrointest Pharmacol Ther 2014;5:1-26.

  30. UpToDate, Clostridium difficile infection in adults: Clinical manifestations and diagnosis, Wolters Kluwer, Citado el 11/08/15. Disponible en: http://www.uptodate.com/ contents/clostridium-difficile-infection-in-adults-clinicalmanifestations- and-diagnosis?source=search_result&sea rch=clostridium+difficile&selectedTitle=2~150.




2020     |     www.medigraphic.com